KRYS
NASDAQ · Biotechnology
Krystal Biotech Inc
$340.21
-3.22 (-0.94%)
Financial Highlights (FY 2026)
Revenue
383.01M
Net Income
201.61M
Gross Margin
94.1%
Profit Margin
52.6%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 94.1% | 49.6% | 49.6% | 49.6% |
| Operating Margin | 41.4% | 16.7% | 15.8% | 19.1% |
| Profit Margin | 52.6% | 12.4% | 11.5% | 12.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 383.01M | 971.92M | 894.90M | 986.11M |
| Gross Profit | 360.33M | 481.90M | 443.71M | 488.93M |
| Operating Income | 158.76M | 162.40M | 141.12M | 188.02M |
| Net Income | 201.61M | 120.52M | 102.54M | 123.97M |
| Gross Margin | 94.1% | 49.6% | 49.6% | 49.6% |
| Operating Margin | 41.4% | 16.7% | 15.8% | 19.1% |
| Profit Margin | 52.6% | 12.4% | 11.5% | 12.6% |
| Rev Growth | — | +7.7% | -5.6% | +0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 2.99B | 2.71B | 2.84B |
| Total Equity | — | 5.06B | 4.99B | 5.78B |
| D/E Ratio | — | 0.59 | 0.54 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 164.39M | 242.82M | 232.68M | 229.91M |
| Free Cash Flow | — | 82.52M | 69.44M | 100.58M |